NFNajla Fakhruddin

Najla Fakhruddin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Najla Fakhruddin has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liposarcoma With Extensive Necrosis Obscuring the Diagnosis in an HIV-Positive Patient: A Potential Diagnostic Pitfall

    by Ali Khrayzat, Souha Kanj, Samer Deeba, Najla Fakhruddin

    Liposarcoma is one of the most common soft tissue sarcomas in adults; however, its occurrence in patients with HIV is rarely reported. High-grade liposarcomas may demonstrate extensive necrosis, which can complicate pathologic evaluation, particularly in limited biopsy material, and may result in misinterpretation as an infectious or reactive process.

  • Open Access

    Characterization and Evaluation of CD24 and NPY as Biomarkers for Metastatic Castration-Resistant Prostate Cancer

    by Peter R. McHenry, Najla Fakhruddin, Kevin Homer, Rui M. Gil da Costa, Lawrence D. True, Colm Morrissey

    Background/Objectives: Prostate cancer is the most diagnosed and third most deadly cancer among men in Europe. Metastatic castration-resistant prostate cancer (mCRPC) is incurable and resistant to standard androgen ablation therapy. More biomarkers are needed to select patients for novel personalized treatments. Previous whole-genome RNA sequencing results indicated a possible role for cluster of differentiation 24 (CD24) and neuropeptide Y (NPY) as diagnostic or prognostic biomarkers in androgen receptor-positive (AR+) mCRPC. Methods: We analyzed tissue microarrays representing 127 primary prostate cancers (with matched adjacent benign prostatic glands) and 124 metastases (from 34 patients) using immunohistochemistry to detect CD24 or NPY. Results: CD24 was more highly expressed in primary prostate cancer than in adjacent benign tissue for nuclear (p: p: p: p: 0.044, d: 0.773). In mCRPC, CD24 was detectable in 76% of cores at the cell membrane and in 58% in the nucleus. NPY was detectable in the cytoplasm of 17%. Scores for NPY and nuclear (but not membranous) CD24 were higher in AR+ mCRPC. In the RNA sequencing results, CD24 did not correlate with AR or kallikrein-related peptidase 3 (KLK3), while NPY positively correlated with AR (rs: 0.313; p: KLK3 (rs: 0.400; p: + mCRPC than AR− neuroendocrine disease, and nuclear CD24 displayed site-specific expression, suggesting a potential role for nuclear CD24 in promoting AR+ mCRPC.

  • Open Access

    Intramuscular Ganglion Cyst of the Extensor Digitorum Longus

    by Ramy Saade, Ahmad Hammad, Jean Paul Rizk, Najla Fakhruddin, Mohamad Nassereddine

    Background: Ganglion cyst is a mucin‐filled synovial cyst. It is the most common mass found in the wrist and hand. However, it is less commonly encountered in the lower extremity and even rarer to be found intramuscularly. Case Presentation: A 34‐year‐old female presented for a symptomatic mass at the anterolateral left knee. Radiography revealed an intramuscular multiseptated cystic lesion within the extensor digitorum longus muscle. No definite solid components or enhancement of the lesion and no intra‐articular extension or capsular communication were observed. Differential diagnosis included intraosseous myxoma and atypical ganglion cyst with inability to exclude malignancy. The patient underwent an open excisional biopsy that corresponded to a ganglion cyst on histopathological assessment. Conclusions: Intramuscular ganglion cysts are rare and underreported in the literature. A thorough differential diagnosis for lesions in uncommon anatomical locations is essential. Surgical excision with histological confirmation remains crucial for diagnostic and therapeutic purposes to rule out malignancy and prevent recurrence.

  • Open Access

    Liquid Biopsy’s Role in Head and Neck Tumors: Changing Paradigms in the Era of Precision Medicine

    by Rudy N. Zalzal, Najla Fakhruddin, Rami Mahfouz

    In the era of precision medicine, liquid biopsy has become an indispensable tool in research and clinical diagnostics. This innovative molecular approach offers significant benefits in managing cancers, such as melanoma, colorectal cancer, lung cancer, and, now, head and neck tumors. By addressing the challenges posed by tumor heterogeneity, liquid biopsy aligns seamlessly with precision medicine strategies, providing more accessible methods to detect and monitor genetic alterations in tumors. While biomarkers for head and neck tumors have been identified, integrating these markers into diagnostic workflows remains a challenge due to the complexities of current sampling techniques. Could liquid biopsy pave the way for a breakthrough in the diagnosis, monitoring, and treatment of patients with head and neck cancer? This review explores the expanding role of liquid biopsy in oncology, with a focus on its potential to revolutionize the management of head and neck malignancies. Liquid biopsy has become an integral part of diagnosis, classification, and prognostication of numerous cancers, namely, head and neck tumors. Liquid biopsy should work in concert with histological testing, imaging, surgery, and other diagnostic and therapeutic approaches, as each offers distinct advantages that together contribute to achieving the best possible patient outcomes.


  • Open Access

    Oral malignant melanoma with colon metastasis mimicking melanosis coli: Case report

    by Noura El Sayegh, Firas Kreidieh, Ghazi Zaatari, Najla Fakhruddin